OKYO PHARMA LTD (OKYO) Stock News

NASDAQ:OKYO - Nasdaq - GG00BMFG5F62 - Common Stock - Currency: USD

3.1 +0.4 (+14.81%)

After market: 3.1602 +0.06 (+1.94%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OKYO Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

17 days ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

17 days ago - By: Benzinga - Mentions: HBIO SRPT MEIP WINT ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

18 days ago - By: Benzinga - Mentions: SSY SRPT CUE PDSB ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: ACCESS Newswire

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

18 days ago - By: OKYO Pharma LTD

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

18 days ago - By: OKYO Pharma LTD

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

2 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the Bio International Convention

2 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the Bio International Convention

3 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

3 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

3 months ago - By: OKYO Pharma LTD

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

3 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

3 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

4 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

4 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

5 months ago - By: OKYO Pharma LTD

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

5 months ago - By: OKYO Pharma LTD

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and CEO Acquire Shares

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and CEO Acquire Shares

6 months ago - By: ACCESS Newswire

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

6 months ago - By: OKYO Pharma LTD

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

6 months ago - By: OKYO Pharma LTD

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

8 months ago - By: OKYO Pharma LTD

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

9 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

9 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

10 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

10 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

a year ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman Acquires Shares

a year ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman Acquires Shares